|Bid||0.000 x 50000|
|Ask||0.000 x 100000|
|Day's Range||117.000 - 120.800|
|52 Week Range||68.505 - 146.000|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology.
CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 125,000 shares of VRTX on 12/11/2017 at an average price of $141.35 a share.
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety ...
NEW YORK, Nov. 15, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Barracuda ...
Research Desk Line-up: Esperion Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Vertex Pharmaceuticals ...
After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.
Research Desk Line-up: Vertex Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Capricor ...
The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) both dropped more than 2%, led lower by a host of disappointing financial results from several big drug makers. The main culprit in today’s pullback is Celgene (CELG). Adding to the pain, Celgene cut its vaunted 2020 sales outlook to a range of $19 billion to $20 billion from the previous target of $21 billion.
Vertex Pharmaceuticals Inc reported a wider third-quarter net loss on Wednesday, on higher costs and onetime items, and raised its outlook for full-year sales of its key cystic fibrosis drugs. The Cambridge, Massachusetts-based biotechnology company posted a net loss of $103 million, or 41 cents a share, compared with a loss of $39 million, or 16 cents a share, a year earlier. Excluding one-time items, Vertex said it earned 53 cents per share.
Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the third quarter ended September 30, 2017. Vertex also increased its total 2017 CF product revenue guidance, including revenue guidance for ORKAMBI® and KALYDECO® , and reiterated its total 2017 combined GAAP and non-GAAP R&D and SG&A expense guidance.
Vertex Pharmaceuticals Incorporated has doubled the number of scholarships for people living with cystic fibrosis and their immediate family members. In its second year, the All in for CF Scholarship program will award 80 scholarships of $5,000 each to help people with cystic fibrosis and their immediate family members pursue two-year, four-year or graduate degrees during the 2018-2019 academic year....
Vertex Pharmaceuticals Inc., on the brink of a breakthrough that could treat nearly all patients with cystic fibrosis, has done everything an investor could ask for in 2017, including double its market ...
Vertex Pharmaceuticals Incorporated today announced a 10-year, $500 million corporate giving commitment focused on providing patient and caregiver support including access to our medicines; expanding our commitment to science, technology, engineering, arts and math education; developing young physicians and scientists; and investing in our communities.
There may be short-term volatility because of the health-care overhaul in Washington, but the long-term thesis is intact. By Phil van Doorn.
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals' (ALXN) Soliris.
Analysts at BTIG laid out the bullish case for owning shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) — a "storied" company with a strong growth outlook. BTIG's Dane Leone initiates ...
The Vetr crowd on Wednesday downgraded its rating of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) from 5 stars (Strong Buy), issued 15 days ago, to 1 star (Strong Sell). Crowd sentiment at the time ...
They’re bullish on Vertex Pharmaceuticals, Boeing and Nvidia, and bearish on Foot Locker, Chipotle and Advance Auto Parts.
Vertex Pharmaceuticals Incorporated today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer . Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice President and Chief Operating Officer Ian Smith.
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a "hold."